Becton Dickinson and Co (NYSE:BDX) Shares Purchased by Prospera Financial Services Inc

Share on StockTwits

Prospera Financial Services Inc lifted its stake in Becton Dickinson and Co (NYSE:BDX) by 11.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 9,859 shares of the medical instruments supplier’s stock after purchasing an additional 992 shares during the quarter. Prospera Financial Services Inc’s holdings in Becton Dickinson and were worth $2,225,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of BDX. Avalon Investment & Advisory acquired a new stake in Becton Dickinson and during the 2nd quarter worth approximately $334,000. Forbes J M & Co. LLP lifted its holdings in Becton Dickinson and by 1.9% during the 2nd quarter. Forbes J M & Co. LLP now owns 31,892 shares of the medical instruments supplier’s stock worth $7,631,000 after buying an additional 591 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in Becton Dickinson and by 17.5% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 1,751 shares of the medical instruments supplier’s stock worth $419,000 after buying an additional 261 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Becton Dickinson and by 1.8% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 363,282 shares of the medical instruments supplier’s stock worth $86,922,000 after buying an additional 6,476 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its position in shares of Becton Dickinson and by 217.6% in the 2nd quarter. Rafferty Asset Management LLC now owns 6,609 shares of the medical instruments supplier’s stock valued at $1,581,000 after purchasing an additional 4,528 shares during the last quarter. Hedge funds and other institutional investors own 85.44% of the company’s stock.

In related news, EVP Patrick Kaltenbach sold 1,272 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $260.00, for a total transaction of $330,720.00. Following the completion of the sale, the executive vice president now owns 10,340 shares in the company, valued at approximately $2,688,400. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.12% of the stock is owned by corporate insiders.

A number of equities research analysts have commented on BDX shares. Morgan Stanley increased their price objective on shares of Becton Dickinson and from $248.00 to $285.00 and gave the company an “equal weight” rating in a research report on Monday, August 10th. Cfra dropped their price objective on shares of Becton Dickinson and from $285.00 to $278.00 and set a “hold” rating on the stock in a research report on Friday, May 8th. Wells Fargo & Co reissued a “buy” rating on shares of Becton Dickinson and in a research report on Friday, May 8th. Goldman Sachs Group started coverage on shares of Becton Dickinson and in a research report on Sunday, May 31st. They issued a “buy” rating and a $278.00 price objective on the stock. Finally, UBS Group increased their price objective on shares of Becton Dickinson and from $265.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Hold” and an average price target of $280.47.

Shares of NYSE BDX traded down $2.10 during mid-day trading on Thursday, reaching $259.90. The company had a trading volume of 24,179 shares, compared to its average volume of 1,290,031. The stock has a market cap of $76.48 billion, a P/E ratio of 93.49, a PEG ratio of 3.26 and a beta of 0.98. The firm has a 50 day simple moving average of $262.93 and a two-hundred day simple moving average of $249.78. The company has a current ratio of 1.45, a quick ratio of 0.97 and a debt-to-equity ratio of 0.71. Becton Dickinson and Co has a 52-week low of $197.75 and a 52-week high of $286.72.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.04 by $0.16. The firm had revenue of $3.86 billion during the quarter, compared to analysts’ expectations of $3.96 billion. Becton Dickinson and had a net margin of 5.30% and a return on equity of 14.19%. Becton Dickinson and’s quarterly revenue was down 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.08 EPS. On average, equities analysts expect that Becton Dickinson and Co will post 9.91 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Tuesday, September 8th. Becton Dickinson and’s dividend payout ratio is currently 27.05%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Net Margin – Understanding the Different Kinds of Profit

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply